Gilead Sciences Inc
NASDAQ:GILD
Gilead Sciences Inc
Revenue
Gilead Sciences Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$56.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$33.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Revenue
$2.2B
|
CAGR 3-Years
39%
|
CAGR 5-Years
59%
|
CAGR 10-Years
46%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$11B
|
CAGR 3-Years
13%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$14.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Gilead Sciences Inc
Revenue Breakdown
Breakdown by Geography
Gilead Sciences Inc
|
Total Revenue:
28.8B
USD
|
|
United States:
20.6B
USD
|
|
Europe:
4.6B
USD
|
|
Rest Of World:
3.5B
USD
|
Breakdown by Segments
Gilead Sciences Inc
|
Total Revenue:
28.8B
USD
|
|
Product Sales:
28.6B
USD
|
|
Royalty, Contract And Other Revenues:
144m
USD
|
Gilead Sciences Inc
Glance View
Gilead Sciences Inc., established in 1987, embarked on its mission with a resolute focus on innovative therapeutic advancements. Nestled in the biotech haven of Foster City, California, Gilead pioneered a path that would see it evolve into a global biopharmaceutical powerhouse. The company’s nucleus is its commitment to discovering, developing, and delivering therapies for diseases with unmet medical needs. Its product portfolio reflects this dedication, notably dominated by groundbreaking advancements in antiviral therapies, particularly for HIV/AIDS, hepatitis B, and hepatitis C. Over the years, its robust research and development engine, fueled by a continual reinvestment of earnings, propelled it to the forefront of tackling complex medical challenges. Its strategic acquisitions, like the pivotal purchase of Pharmasset in 2011, underpinned its ascent in the hepatitis C treatment arena, highlighting its aptitude for identifying and integrating synergistic growth opportunities. Financially, Gilead generates its revenue through the commercialization of its pharmaceutical portfolio. It thrives on a model where its novel therapies, once developed and approved, are sold to healthcare providers and systems. The landscape of antiviral treatments, primarily the revolutionary HIV regimen and hepatitis C cures like Harvoni and Sovaldi, serves as the backbone of its revenue stream. Meanwhile, Gilead's ventures into oncology and inflammatory diseases through strategic acquisitions and partnerships aim to diversify its portfolio beyond infectious diseases. The intricate process from innovation to distribution underscores Gilead’s proficient use of its clinical expertise and market acumen to address both expanding global health needs and shareholder demands, ensuring its enduring presence in the volatile seas of the biotech industry.
See Also
What is Gilead Sciences Inc's Revenue?
Revenue
28.8B
USD
Based on the financial report for Dec 31, 2024, Gilead Sciences Inc's Revenue amounts to 28.8B USD.
What is Gilead Sciences Inc's Revenue growth rate?
Revenue CAGR 10Y
1%
Over the last year, the Revenue growth was 6%. The average annual Revenue growth rates for Gilead Sciences Inc have been 2% over the past three years , 5% over the past five years , and 1% over the past ten years .
You don't have any saved screeners yet